MX2021005352A - Tratamiento y diagnóstico de enfermedades oculares mediadas por autoanticuerpos. - Google Patents

Tratamiento y diagnóstico de enfermedades oculares mediadas por autoanticuerpos.

Info

Publication number
MX2021005352A
MX2021005352A MX2021005352A MX2021005352A MX2021005352A MX 2021005352 A MX2021005352 A MX 2021005352A MX 2021005352 A MX2021005352 A MX 2021005352A MX 2021005352 A MX2021005352 A MX 2021005352A MX 2021005352 A MX2021005352 A MX 2021005352A
Authority
MX
Mexico
Prior art keywords
present disclosure
autoantibody
diagnosis
treatment
active compound
Prior art date
Application number
MX2021005352A
Other languages
English (en)
Inventor
Jain Sandeep
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2021005352A publication Critical patent/MX2021005352A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación proporciona una formulación oftálmica que comprende uno o más excipientes farmacéuticamente aceptables; un compuesto farmacéuticamente activo que es capaz de reducir la cantidad o las acciones perjudiciales de los autoanticuerpos sobre la superficie ocular, tales como IgG. En particular, la presente divulgación proporciona una formulación oftálmica donde el compuesto farmacéuticamente activo es capaz de tratar una afección clínica seleccionada del grupo que consiste en una enfermedad inflamatoria, infecciosa e inmunitaria de la superficie ocular o intraocular que puede causar síntomas de molestia ocular, queratitis, enfermedad del ojo seco, formación de simbléfaron, escorzo del fórnix, queratinización conjuntival/del borde palpebral, fibrosis subconjuntival, gliosis retiniana y glaucoma.
MX2021005352A 2018-11-08 2019-11-08 Tratamiento y diagnóstico de enfermedades oculares mediadas por autoanticuerpos. MX2021005352A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862757641P 2018-11-08 2018-11-08
US201962855253P 2019-05-31 2019-05-31
PCT/US2019/060566 WO2020097528A1 (en) 2018-11-08 2019-11-08 Treatment and diagnosis of autoantibody-mediated eye diseases

Publications (1)

Publication Number Publication Date
MX2021005352A true MX2021005352A (es) 2021-09-14

Family

ID=69056109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005352A MX2021005352A (es) 2018-11-08 2019-11-08 Tratamiento y diagnóstico de enfermedades oculares mediadas por autoanticuerpos.

Country Status (10)

Country Link
US (1) US20220062337A1 (es)
EP (1) EP3877406A1 (es)
JP (1) JP2022512946A (es)
KR (1) KR20210093274A (es)
CN (1) CN113631570A (es)
AU (1) AU2019377552A1 (es)
BR (1) BR112021008548A2 (es)
CA (1) CA3118367A1 (es)
MX (1) MX2021005352A (es)
WO (1) WO2020097528A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100002306A1 (it) * 2021-02-03 2022-08-03 Univ Degli Studi Roma La Sapienza Procedimento e kit per la diagnosi in vitro della sindrome da anticorpi anti-fosfolipidi
US11951123B2 (en) * 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
WO2023201283A2 (en) * 2022-04-13 2023-10-19 The Regents Of The University Of California Methods of producing plasma or serum and uses thereof
WO2024077068A1 (en) * 2022-10-06 2024-04-11 Oklahoma Medical Research Foundation Anti-vimentin antibodies are associated with higher severity of sjögren's syndrome
WO2024136368A1 (ko) * 2022-12-21 2024-06-27 건국대학교 산학협력단 α-2,6-시알산화 면역글로불린의 안구 건조증 또는 염증성 안과 질환의 예방 또는 치료 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984492B2 (en) * 2003-09-05 2006-01-10 Talecris Biotherapeutics, Inc. Methods and compositions for treating herpes infections
AU2012392760C1 (en) * 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins

Also Published As

Publication number Publication date
BR112021008548A2 (pt) 2021-08-03
CA3118367A1 (en) 2020-05-14
EP3877406A1 (en) 2021-09-15
JP2022512946A (ja) 2022-02-07
KR20210093274A (ko) 2021-07-27
WO2020097528A1 (en) 2020-05-14
CN113631570A (zh) 2021-11-09
US20220062337A1 (en) 2022-03-03
AU2019377552A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2021005352A (es) Tratamiento y diagnóstico de enfermedades oculares mediadas por autoanticuerpos.
JP2015509500A5 (es)
JP2015134824A5 (es)
Butrus et al. Vernal keratoconjunctivitis and keratoconus
HRP20211589T1 (hr) Uporaba proteoglikana 4 (prg4) za poboljšanje dinamičke vizuelne oštrine i aberacija višeg reda
Czajka et al. Comparison of 1.8‐mm incision versus 2.75‐mm incision cataract surgery in combined phacoemulsification and 23‐gauge vitrectomy
HALABIS Analysis of the corneal endothelium in keratoconus
Dahl et al. The use of continuous-wear silicone contact lenses in the optical correction of aphakia
Ahn et al. Changes in spherical aberration after various corneal surface ablation techniques
JP7299889B2 (ja) 緑内障を治療するためのＷｎｔ５ａの調節
Tragakis et al. Hydrophilic contact lenses for correcting irregular and high astigmatism
Pradipta et al. Uveitic glaucoma management with recurrent uveitis episode
US20180221417A1 (en) Treatment of dry eye using amnion released factors
Volzhanin et al. Morphologic basis of the refraction shift after penetrating glaucoma surgery
Lee et al. Retinal complications after refractive surgery
Ryu et al. Comparison of Anterior Chamber Depth with Posture Change Between Primary and lens-induced Angle Closure Glaucomas
Grodsky et al. Medical management and visual rehabilitation of limbal niche dysfunction
Kornblueth et al. Sympathetic ophthalmia following an operation for retinal detachment
Koukkoulli et al. An unusual presentation of aqueous misdirection
George et al. Subconjuntival cilia
Yusef et al. Congenital Aniridia: Clinical Features and Therapeutic Approaches (Case Report)
Milash et al. Changes of corneal epithelial thickness before and after OK-correction according to SD-OCT
Neroeva et al. An integrated analysis of clinical and morphometric indications of atrophic forms of age-related macular degeneration
Slabaugh Secondary Angle Closure due to Crystalline Lens Dislocation in a Patient with Atopic Dermatitis and Chronic Eye Rubbing
Singh et al. Severe Anterior Capsular Contraction Syndrome Presenting With Hypotony and Hyperopic Shift in A High Myope With History of Scleral Buckling